Several domestic drug makers, including Mankind Pharma, have launched the diabetes drug Empagliflozin at significantly reduced prices following the expiration of Boehringer Ingelheims patent. Mankind ...

Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed SGLT2 inhibitor for type-2 diabetes ...

According to the company's statement, these medications are designed to improve glycemic control in adults with Type 2 Diabetes while also reducing cardiovascular outcomes in the patients.

Glenmark Pharmaceuticals launches Empagliflozin, an SGLT2 inhibitor, in India under the brand name Glempa for glycemic control and weight-loss in diabetes patients.

Glenmark Pharmaceuticals announced that it has launched generic Empagliflozin, a widely recognized SGLT2 inhibitor, in India.

Glenmark Pharmaceuticals announced today the launch of Empagliflozin and its fixed-drug combinations in India under the brand names Glempa, Glempa-L, and Glempa-M. The shares of Glenmark ...

Glenmark Pharmaceuticals has launched Empagliflozin, a widely recognized SGLT2 inhibitor, in India. The drug has been introduced under the brand name Glempa (Empagliflozin 10/25 mg), along with its ...